Pfizer Inc, which in May abandoned its $118 billion bid to purchase AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals.The largest U.S. drugmaker reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines. But overall sales fell on competition with newer rival drugs and cheaper generics, trends that have quickened Pfizer's efforts to buy companies and drugs that can bolster its medicine chest.Under UK takeover rules, AstraZeneca can attempt to re-engage with Pfizer in August, and Pfizer can make another run at AstraZeneca in November. But Pfizer officials on Tuesday gave no hints of whether they would do so."I think it's best to remain silent," Chief Executive Officer Ian Read said on an investor conference call, citing the UK rules.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN fell by 0.43% or $-0.32/share to $73.57. In the past year, the shares have traded as low as $48.53 and as high as $82.68. On average, 4668350 shares of AZN exchange hands on a given day and today's volume is recorded at 2689217.
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. Shares of PFE fell by 0.12% or $-0.035/share to $30.06. In the past year, the shares have traded as low as $27.76 and as high as $32.96. On average, 26472700 shares of PFE exchange hands on a given day and today's volume is recorded at 17369458.
Source
